New dyslipidaemia guidelines drawn up by the American College of Cardiology and the American Heart Association (ACC/AHA) incorporate new and updated recommendations for atherosclerotic cardiovascular disease (ASCVD) risk assessment in patients with elevated TG, and for the management of hypertriglyceridaemia (HTG).
Pemafibrate may improve liver fibrosis in MASLD
Pemafibrate may improve liver fibrosis, lipid metabolism and liver enzyme levels, according to results of a retrospective study of magnetic resonance elastrography (MRE) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridaemia (HTG).1
Novel therapies in hypertriglyceridaemia: Trial results in 2025 and what’s to come in 2026
Novel therapies for hypertriglyceridaemia (HTG) reached some major milestones in 2025 including impressive clinical trial results across the three targets for these emerging treatments – ANGPTL3, ANGPTL4 and apoC3 – and the first regulatory approvals for apoC3 inhibitors in patients with familial chylomicronaemia syndrome (FCS). Just as exciting are expectations for 2026, as studies of apoC3-targeting agents continue down the HTG pyramid of severity and ANGPTL3 and ANGPTL4-targeting agents advance from early into later phase clinical trials.
Olezarsen reduces need for health services in FCS
Olezarsen reduces all-cause health services utilisation and improves treatment experience for patients with familial chylomicronaemia syndrome (FCS). This is the finding from a recently published resource utilisation analysis of results from the Balance trial of olezarsen in patients with genetically identified FCS.
SHR-1918 shows promise in homozygous FH
The ANGPTL3-targeting agent, SHR-1918, significantly reduced LDL-C, TG, apoB and other atherogenic lipids in patients with homozygous familial hypercholesterolemia (HoFH) in a single arm, Phase 2 non-randomised study carried out at eight sites in China.
Fish oil supplements reduce serious CV events in patients on haemodialysis
Patients undergoing maintenance haemodialysis who take daily n-3 fatty acid supplements can reduce their rates of serious cardiovascular (CV) events, according to recently published results of the PISCES trial.
